The Philadelphia Inquirer recently covered Fideres’s recent research on price increases of generic drugs as part of a full examination of the pharmaceutical industry.
Alberto Thomas, founding partner at Fideres, is quoted as describing the price increases as occurring « without any meaningful increases in the costs of materials or production costs or breakdown of factories or other disruption to the supply chain. That’s what makes this very suspicious. »
The full article by the Philadelphia Inquirer can be found here.